DCGI Orders Novartis To Explain Possible Drug-Filing Irregularities
This article was originally published in PharmAsia News
Executive Summary
Novartis has been ordered by India regulators to explain an allegedly fraudulent filing the Swiss drug maker made for a veterinary drug, the issue having to do with its origin.